Report cover image

Stargardt Disease Therapeuticss Market

Publisher Coherent Market Insights
Published Sep 04, 2023
Length 167 Pages
SKU # CMI18237985

Description

Stargardt Disease Therapeuticss Market, By Drug Type (Emixustat, LBS-008, others (Gildeuretinol), By Age Group (Children (Below 17 Years) and Adult (Above 17 Years)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Stargardt disease is a genetic condition that is caused by a tiny alteration in a single gene. It is also known as fundus flavimaculatus, and is the most common form of macular dystrophy. It affects approximately one in 10,000 people and affects both males and females. Stargardt causes a wasting of a central area of the retina called the macula. This area is eventually surrounded by a ring of white or yellow spots. An important layer of the retina, the retinal pigment epithelium (RPE), is also affected by an accumulation of ‘waste’ material called lipofuscin. Being diagnosed with Stargardt disease can be distressing, but with the right information and support, people can cope very well. It is important to remember that in the vast majority of cases, patients with stargardt disease do not lose all their sight. Stargardt disease usually affects central vision only. Peripheral vision is not usually affected. There is a great deal of research going on into potential treatments. Thus, introduction of such advanced treatment options in the market is expected to drive global stargardt disease therapeutics market growth over the forecast period.

Market Dynamics

The key players in the medical devices industry are focusing on the development of therapeutic drugs for various patient pool suffering from Stargardt disease. Thus, introduction of such advanced drugs in the market is expected to drive growth of the global stargardt disease therapeuticss market over the forecast period. For instance, on June 05, 2023, Alkeus Pharmaceuticals, a biopharmaceutical company, announced that the company had raised a US$ 150 million in Series B financing to support the registration and launch of gildeuretinol (ALK-001), a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness in children and young adults. The financing was led by Bain Capital Life Sciences, with additional participation by TCGX, Wellington Management and Sofinnova Investments.

Key features of the study:
  • This report provides an in-depth analysis of the global stargardt disease therapeuticss market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global stargardt disease therapeuticss market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd, ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., Hoffmann-La Roche AG, Ocugen, Inc., Ascidian Therapeutics, Nanoscope Therapeutics Inc., Aequus Pharmaceuticals Inc., Fera Pharmaceuticals, LLC, Insmed Incorporated, Belite Bio, Inc., and SpliceBio
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global stargardt disease therapeuticss market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global stargardt disease therapeuticss market
Detailed Segmentation:
  • Global Stargardt Disease Therapeuticss Market, By Drug Type:
  • Emixustat
  • LBS-008
  • Others (Gildeuretinol)
  • Global Stargardt Disease Therapeutics Market, By Age Group:
  • Children (Below 17 Years)
  • Adult (Above 17 Years)
  • Global Stargardt Disease Therapeutics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Stargardt Disease Therapeutics Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • Company Profiles
  • Kubota Pharmaceutical Holdings Co., Ltd.
  • Stargazer Pharmaceuticals Inc.
  • Iveric Bio, Inc.
  • Sanofi S.A.
  • Alkeus Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • CHABiotech CO., Ltd
  • ReVision Therapeutics, Inc
  • Lin BioScience, Inc.
  • Biogen Inc.
  • Hoffmann-La Roche AG
  • Ocugen, Inc.
  • Ascidian Therapeutics
  • Nanoscope Therapeutics Inc.
  • Aequus Pharmaceuticals Inc.
  • Fera Pharmaceuticals, LLC
  • Insmed Incorporated
  • Belite Bio, Inc.
  • SpliceBio

Table of Contents

167 Pages
1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Age Group
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Epidemiology
4. Global Stargardt Disease Therapeutics Market – COVID-19 Impact Analysis
Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand
5. Global Stargardt Disease Therapeutics Market, By Drug Type, 2018–2030, (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
Emixustat
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
LBS-008
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
Others (Gildeuretinol)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
6. Global Stargardt Disease Therapeutics Market, By Age Group, 2018–2030, (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
Children (Below 17 Years)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
Adult (Above 17 Years)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Segment Trends
7. Global Stargardt Disease Therapeutics Market, By Distribution Channel, 2018–2030, (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Mn)
8. Global Stargardt Disease Therapeutics Market, By Region, 2018–2030, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2023 and 2030 (%)
Y-o-Y Growth Analysis, For Region, 2018–2030
Segment Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2018–2030, (US$ Mn)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Company Profiles
Kubota Pharmaceutical Holdings Co., Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Stargazer Pharmaceuticals Inc.
Iveric Bio, Inc.
Sanofi S.A.
Alkeus Pharmaceuticals Inc.
Astellas Pharma Inc.
CHABiotech CO., Ltd
ReVision Therapeutics, Inc.
Lin BioScience, Inc.
Biogen Inc.
F.Hoffmann-La Roche AG
Ocugen, Inc.
Ascidian Therapeutics
Nanoscope Therapeutics Inc.
Aequus Pharmaceuticals Inc.
Fera Pharmaceuticals, LLC
Insmed Incorporated
Belite Bio, Inc.
SpliceBio
10. Section
References
Research Methodology
About us and Sales Contact
*Browse 35 market data tables and 30 figures on “Global Stargardt Disease Therapeutics Market” – Global forecast to 2030

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us